Liyun Gong MD,PhD_Biochemistry & Molecular Biology_School of Basic Medical Sciences_Faculty & Staff

Professor Gong obtained her M.D. and Ph.D. degrees from the Zhongshan School of Medicine, Sun Yat-sen University, in 2008. Prior to this, she earned her bachelor’s and master’s degrees in related medical disciplines from Dalian Medical University in 1997 and 2005, respectively. In September 2008, she joined the Department of Biochemistry and Molecular Biology, Medical School of Shenzhen University, where she was progressively promoted from Associate Professor to Professor. During 2015 to 2016, she served as a Guest Researcher at the National Cancer Institute (NCI), National Institutes of Health (NIH), United States, which further enriched her international research experience.

Professor Gong’s research has focused on deciphering the molecular mechanisms underlying acquired drug resistance and metastasis in solid tumors, as well as developing targeted inhibitors to reverse drug resistance and inhibit tumor progression. She has presided over more than 14 research projects at the national, provincial, and municipal levels, and achieved a series of innovative findings, clarifying key molecular mechanisms that mediate drug resistance, epithelial-mesenchymal transition, tumor metastasis, and ferroptosis evasion in malignant tumors.

Her research findings have been published in several top-tier international academic journals, including Advanced Science, Oncogene, and Cell Death & Disease, with the total number of citations reaching 1252. Based on the mechanistic insights into the role of SRPK1 in NSCLC drug resistance, Professor Gong and her team have developed novel targeted strategies and obtained two authorized Chinese invention patents.

These achievements reflect the effective translation of basic research into practical applications, laying a solid foundation for the development of novel precision therapeutics for cancer patients and demonstrating Professor Gong’s dedication to translational medicine.

RESEARCH INTERESTS:

Primary and acquired resistance mechanisms of EGFR-TKIs in NSCLC

EGFR-TKIs resistance and metabolic reprogramming

Identification of novel EGFR-TKIs targets in EGFR-WT NSCLC.

PROFESSIONAL MEMBERSHIP AND ACTIVITIES

l Council Member, the 1^st Shenzhen Society of Biochemistry and Molecular Biology (01/2015-12/2018)

l Council Member, the 2^nd Shenzhen Society of Biochemistry and Molecular Biology (01/2019-12/2022)

l Council Member, the 3^rd Shenzhen Society of Biochemistry and Molecular Biology (01/2023-12/2026)

l Standing Member, at the 1st Congress of the Teaching SpecialtyCommittee of Guangdong Society of Biochemistry and Molecular Biology (03/2024--03/2029)

l Standing Member, the Specialty Committee of Targeted Drug Therapy of Guangdong Pharmacological Society (10/2022-10/2026)

l Member, Pharmaceutical Teacher Development Professional Committee, Guangdong Medical Education Association (03/2018-03/2023)

l Member, the 1st Specialty Committee of Biochemistry and Molecular Biology of Guangdong Medical Education Association (03/2018-03/2023)

l Member, the Information Technology Development Working Committee of the Sixth Undergraduate Teaching Steering Committee of Shenzhen University (12/2019-Present)

l Member, the Second Medical Education Development Center of the Medical School (10/2022-10/2025)

RESEARCH PROJECTS (PRINCIPAL INVESTIGATOR):

1. General Program, National Natural Science Foundation of China (No.82373345): Mechanistic study on SRPK1/β-catenin regulating EGFR membrane localization and phosphorylation mediating osimertinib acquired resistance in NSCLC, 2024.01–2027.12, ¥480,000

2. Frontier Exploratory Program (General), Shenzhen Medical Academy (No.B2302046): Molecular mechanism of LincRNA2035 regulating brain-bone metastasis transition in lung cancer, 2024.01–2026.12, ¥3,000,000

3. General Program, National Natural Science Foundation of China (No.81872448): Mechanistic research on SRPK1-induced oxaliplatin resistance in colon cancer, 2019.01–2022.12, ¥530,000

4. General Program, Natural Science Foundation of Guangdong Province (No.2022A1515012206): Mechanism of SRPK1 spacer domain promoting EGFR-TKIs resistance in T790M-mutant NSCLC, 2022.01–2024.12, ¥100,000

5. Basic Research Program, Shenzhen Science and Technology Innovation Commission (No.JCYJ20210324093203008): Mechanistic study of SRPK1 non-kinase domain promoting EGFR-TKIs resistance in T790M-mutant NSCLC and development of related inhibitors, 2021.10–2024.10, ¥600,000

6. Basic Research Program, Shenzhen Science and Technology Innovation Commission (No.JCYJ20180305163414905): SRPK1 regulates colon cancer anti-apoptosis through abnormal alternative splicing and SRPK1/Akt/NF-κB pathway, 2019.03–2021.03, ¥300,000

7. Young Scientists Fund, National Natural Science Foundation of China (No.81101501): Molecular mechanism of sphingosine kinase 1 (SPHK1) in anti-apoptosis of human glioma cells, 2012.01–2014.12, ¥240,000

8. Medical Science Foundation of Guangdong Province (No.A2018265): Molecular mechanism of serine/arginine protein kinase SRPK1 in colon cancer anti-apoptosis, 2018.07–2020.06, ¥5,000

9. Medical Science Foundation of Guangdong Province: Molecular mechanism of GOLPH3 promoting cancer stem cell properties and inducing NSCLC metastasis, 2017.07–2019.06, ¥10,000

10. Basic Research Program, Shenzhen Science and Technology Innovation Commission (No.JCYJ20170302144320949): Mechanism of serine/arginine protein kinase SRPK1 promoting non-small cell lung cancer resistance via anti-apoptosis, 2017.05–2019.05, ¥400,000

11. Basic Research Program, Shenzhen Science and Technology Innovation Commission (No.JCYJ20140828165255312): Mechanistic study of Golgi phosphoprotein 3 in promoting lung cancer metastasis and development of small molecule modulators, 2014.08–2016.08, ¥300,000

12. Basic Research Program, Shenzhen Science and Technology Innovation Commission (No.JCYJ20120613110335842): Molecular mechanism of proto-oncogene SOX9 inducing early metastasis of lung cancer, 2012.06–2014.06, ¥100,000

PUBLICATIONS:

Note: † First author; * Corresponding author; IF = Impact Factor; Top J = Top Journal in the field

1. Li M, Yu X, Liu Y, et al., Gong L* (co-corresponding). KRAS/ABHD17C/ALOX15B Axis Promotes Pancreatic Cancer Progression via Ferroptosis Evasion. Advanced Science 2025;12(35):e04470. (IF=14.1, CAS Tier 1, Top J)

2. Huang JQ†, Duan LX†, Liu QY†, et al., Gong LY*. SRPK1 promotes EGFR-TKI resistance by enhancing GSK3β Ser9 autophosphorylation independent of its kinase activity in NSCLC. Oncogene 2023;42(15):1233-1246. (IF=8.7, CAS Tier 1, Top J)

3. Gong LY†*, Tu T, Zhu J, et al. Golgi phosphoprotein 3 induces autophagy and EMT to promote metastasis in colon cancer. Cell Death Discovery 2022;8(1):76. (IF=7.38, CAS Tier 2)

4. Song JW†, Zhu J†, Wu XX, et al., Gong LY*. GOLPH3/CKAP4 promotes metastasis and tumorigenicity by enhancing exosomal WNT3A secretion in NSCLC. Cell Death & Disease 2021;12(11):1-16. (IF=9.7, CAS Tier 1, Top J)

5. Ross C, Gong LY, Jenkins LM, et al. SMARCD1 is an essential expression-restricted metastasis modifier. Communications Biology 2024;7(1):1299. (IF=5.2, CAS Tier 1, Top J)

6. Huang JQ†, Li HF†, Zhu J, et al., Gong LY*†. SRPK1/AKT axis promotes oxaliplatin-induced anti-apoptosis via NF-κB activation in colon cancer. Journal of Translational Medicine 2021;19:280. (IF=8.4, CAS Tier 2)

7. Huang JQ†, Wei FK†, Xu XL†, et al., Gong LY*. SOX9 drives EMT in NSCLC through the Wnt/β-catenin pathway. Journal of Translational Medicine 2019;17:143. (IF=4.5, CAS Tier 2)

8. Gong LY†, Song JW†, Lin X†, et al. SRPK1 Promotes a Cancer Stem Cell-like Phenotype through Activation of Wnt/β-catenin Signaling in NSCLC. Journal of Pathology 2016;240:184-196. (IF=7.2, CAS Tier 1, Top J)

9. Yu R†, Hu Y†, Zhang S†, et al., Gong LY, Li J*. LncRNA CTBP1-DT-encoded microprotein DDUP sustains DNA damage response signalling to trigger dual DNA repair mechanisms. Nucleic Acids Research 2022;50(14):1-18. (IF=18.75, CAS Tier 1, Top J)

10. Tingting Sun, Yanfen Hu, Weipeng He, Yuru Shang, Xiaohong Yang, Liyun Gong, Xianbin Zhang, Peng Gong, Guofen Yang SRT2183 impairs ovarian cancer by facilitating autophagy. AGING (2020),Vol.12,No.23 (IF=5.9，CAS Tier 2)

11. Xing-hua Li, Jun-wei Song, Jun-ling Liu, Shu Wu, Le-shi Wang, Li-yun Gong*(co-corresponding) and Xi Lin*. Serine–arginine protein kinase 1 is associated with breast cancer progression and poor patient survival. Medical Oncology (2014) 31:83 DOI 10.1007/s12032-014-0083-8 (IF=2.6 )

12. Liu J, Yin X, Liu B, Zheng H, Zhou G, Gong L, Li M, Li X, Wang Y, Hu J, Krishnan V, Zhou Z, Wang Z. HP1α mediates defective heterochromatin repair and accelerates senescence in Zmpste24-deficient cells. Cell Cycle (2014), 14;13(8). (IF=3.5 CAS Tier 2)

13. Chun-Hui Zhou, Li-Ping Ye, Yan Li, Xin-Yin Zhang, Xin-Yu Xu, Li-Yun Gong*. Clinical significance of SOX9 in human non-small cell lung cancer progression and overall patient survival. Journal of Experimental & Clinical Cancer Research (2012) 31:18.

14. Gong LY†, Li J, Song LB*, et al. Oncoprotein Bmi-1 Renders Apoptotic Resistance to Glioma Cells through Activation of the IKK-NF-κB Pathway. The American Journal of Pathology 2010;176(2):699-709. (IF=4.05, CAS Tier 1, Top J)

15. Li J†, Guan HY†, Gong LY†, et al. Clinical significance of sphingosine kinase-1 expression in human astrocytomas progression and survival. Clinical Cancer Research 2008;14(21):6996-7003. (IF=9.6, CAS Tier 1, Top J)

16. Li J*, Zhang N*, Song LB*, Liao WT, Jiang LL, Gong LY, Wu J, Yuan J, Zhang HZ, Zeng MS, Li M. Astrocyte elevated gene-1 is a novel prognostic marker for breast cancer progression and overall patient survival Clin Cancer Res (2008);14(11):3319-26.（IF=9.6，CAS Tier 1, Top J）

PATENTS (INVENTOR, AUTHORIZED)

1. Gong LY, Huang JQ, Duan LX. Application of SRPK1 inhibitor spacer in preparing drugs for reducing gefitinib resistance in NSCLC treatment. Patent No. ZL 202211167521.7, Shenzhen University, Authorization Date: 2023.09.01 (China)

2. Gong LY, Huang JQ. A biotinylated gefitinib probe, its preparation method and application. Patent No. ZL 202411950792.9, Shenzhen University, Authorization Date: 2025.11.25 (China)

TEXTBOOK COMPILATION & TRANSLATION

1. Co-compiler, Biochemistry (5th Edition) (ISBN:978-7-5659-3065-2), Peking University Medical Press, 2024, Contributed 50,000 Chinese characters

2. Co-compiler, Medical Biochemistry (1st Edition) (ISBN:978-7-89505-169-0), Science Press, 2023, Contributed 50,000 Chinese characters

3. Co-translator, Atlas of Neurotherapeutics in Pain (2nd Edition), People's Medical Publishing House, 2021, Contributed 50,000 Chinese characters

4. Co-compiler, Easy Learning of Biochemistry and Molecular Biology (2nd Edition), Peking University Medical Press, 2015, Contributed 30,000 Chinese characters

5. Co-compiler, Biochemistry Exercise Book (National Planning Textbook for Undergraduate Education), Peking University Medical Press, 2014, Contributed 30,000 Chinese characters

6 . Co-compiler, Dust Mites and Allergic Diseases (1st Edition), Science Press, 2014, Contributed 30,000 Chinese characters

HONORS/AWARDS

l The First Prize in the Seventh Basic Medicine Academic Annual Conference and the 2024 Labor Union Intellectual Competition.September 2024

l Outstanding Master's Advisors in the School of Basic Medical Sciences, Shenzhen University Medical School.September 2024

l The Second Prize for your academic poster presentation at the Fifth Basic Medicine Academic Annual Conference of Shenzhen University Medical School. August 2022

l The Most Popular Undergraduate Teacher Award by Shenzhen University Medical School for the 2019-2020 academic year. March 2021

l Outstanding performance and excellent assessment results during the 2020-2021 academic year of Shenzhen University. September 2021

l Outstanding Undergraduate Teacher Award, a Special Teaching Award of Shenzhen University. April 2021

l The Organizational Management Award in the First Shenzhen University Medical School Young Teachers Teaching Competition. December 2020

l The Second Prize for Outstanding Academic Paper by Shenzhen University Medical School for the year 2019. January, 2020

l The First Prize for High-Level Research Project" by Shenzhen University Medical School for the year 2018. January 2019

l Outstanding performance and excellent assessment results during the 2017-2018 academic year of Shenzhen University. September 2018

l Third Prize, 1st National Micro-lecture Competition on Biochemistry and Molecular Biology 2016 National Biochemistry Micro-Lecture Competition. October 2016

l Outstanding Undergraduate Course Award for the 2015-2016 Academic Year of Shenzhen University (Ranked fourth). November 2016

l The Second Prize in the Excellent Poster Competition of the Youth Forum of the 1st Medical Branch of the Chinese Society of Biochemistry and Molecular Biology. April 2016

l Guest Researcher, Metastasis Susceptibility Section, LCBG National Cancer Institute (NCI) National Institutes of Health (NIH). March 2015

l The Third Prize of the First Batch of Excellent Educational Science Achievements of the 10th Five-Year Plan Period in Liaoning Province. January 2004

l The First Prize, Dalian Medical University Teaching Achievement Award. December 2004

TEACHING AWARDS & MENTORING HONORS

l The master's degree thesis "Mechanism of SRPK1 Promoting EGFR-TKI Resistance and Design of Short Peptide Inhibitors Targeting Its Spacer Domain", supervised by Gong Liyun, was selected as one of the 100 Excellent Master's Degree Theses in the Selection of Excellent Graduate Degree Theses of Shenzhen University. June 2024.

l National Second Prize, 9th National Undergraduate Basic Medical Innovation Research and Experimental Design Forum (Belt and Road International Forum): Design of small molecule inhibitor targeting SRPK1 Spacer domain to improve EGFR-TKIs resistance in NSCLC, Award-winning Team Members: Huang Zhenpeng, Qin Qingdong, Yuan Shiwei, Supervisor: Gong Liyun, August 2023

l Silver Award in Experimental Design of the National Excellent Achievement Award at the Final of the 9th National College Students’ Forum on Innovation Research and Experimental Design In Basic Medical Sciences to students Huang Zhenpeng, Qin Qingdong, Yuan Shiwei, Supervisor: Gong Liyun, August 2023

l Educational Reform Projects (Principal Investigator)：University-level Educational Reform Project, Shenzhen University (No.JG2020072): Construction and integration of teaching team for molecular medicine platform-related disciplines (Biochemistry, Cell Biology, Genetics), 2020.11

l The Third Prize be awarded to Gong Liyun for guiding the Creation of work “SOX9 Promotes the Epithelial-Mesenchymal Transition in Non-Small-Cell Lung Cancer by Activating Wnt/β-Catenin Pathway” in in the academic track of “Li Yuan Challenge” Innovation and Entrepreneurship Competition of Shenzhen University in December 2019.

l The Merit Award in the Second "Undergraduate Basic Medicine Innovation Forum and Experimental Design Competition" of the School of Basic Medical Sciences, Health Science Center, Shenzhen University to student Chen Guanzi, Supervisor: Gong Liyun, June 2019

l The third Prize be awarded to Gong Liyun for guiding the Creation of work “SOX9 Promotes the Epithelial-Mesenchymal Transition in Non-Small-Cell Lung Cancer by Activating Wnt/β-Catenin Pathway” in Shenzhen University “Challenge Cup” Undergraduate Extracurricular Academic Science and Technology Works in December 2018.

l The third Prize be awarded to Gong Liyun for guiding the Creation of work “The Mechanism Study of Serine-Arginine Protein Kinase 1 (SRPK1) Promoting Drug Resistance in NSCLC via Anti-apoptosis” in Shenzhen University “Challenge Cup” Undergraduate Extracurricular Academic Science and Technology Works in December 2017.

l The Excellent Achievement Award in the 4th National College Students’ Innovation Forum and Experimental Design Competition on Basic Medical Sciences to Liang Jin, Chen Yu, Liu Siying, You Moxi, Supervisor: Gong Liyun, June 2016

l Guangdong Provincial undergraduate training programs for Innovation and Entrepreneurship Training Program Project Completion ranked as: Excellent Principle project investigator: Zhang Xinyin, Research group members: Li Yan, Xu Xinyu Project mentor: Gong Liyun, April 2015

l The Second Prize in the 3rd National College Students’ Innovation Forum and Experimental Design Competition on Basic Medical Sciences to students Chen Yu, Xu Xinyu, Liang Jin, Liu Xingqi, Supervisor: Gong Liyun, October 2014

l The Excellent Award in the 2nd National College Students’ Innovation Forum and Experimental Design Competition on Basic Medical Sciences to students Li Yan, Zhang Xinyin, Xu Xinyu, Supervisor: Gong Liyun, November 2012

l The Excellent Award in the 2nd National College Students’ Innovation Forum and Experimental Design Competition on Basic Medical Sciences to students Zhang Xinyin, Li Yan, Xu Xinyu, Supervisor: Gong Liyun, November 2012